CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Zhang, Y ^a,b,c   Patel, S ^a,b,c   Abdelouahab, H ^a,c,d   Wittner, M ^a,b,c   Willekens, C ^a,b,c   Shen, S ^b,c,e   Betems, A ^a,b,c   Joulin, V ^a,b,c   Opolon, P ^c   Bawa, O ^c   Pasquier, F ^b,c   Ito, M ^f   Fujii, N ^g   Gonin, P ^c   Solary, E ^a,b,c   Vainchenker, W ^a,b,c   Coppo, P ^a,h,i   De Botton, S ^a,b,c   Louache, F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Gustave Roussy   (France)

^f CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h Département d'Hématologie HÔpital Necker   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

Acute myeloid leukemia; CXCL12; CXCR4; Inhibitors; Leukemia initiating cells; Niche

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; TN 140; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW; CELL DEATH; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA INITIATING CELL; MALE; MOUSE; NONHUMAN; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELLS AND CELL LINES; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-HIV AGENTS; APOPTOSIS; CHEMOKINE CXCL12; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; RECEPTORS, CXCR4; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84870568258     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.137     Document Type: Article

References (45)

1. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-120.
2. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-833.
3. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-lineadapted HIV-1. Nature 1996; 382: 833-835.
4. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-9453.
5. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599.
6. Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 1998; 10: 179-185.
7. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777-783.
8. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-3296.
9. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-2989.
10. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
11. Foudi A, Jarrier P, Zhang Y, Wittner M, Geay JF, Lecluse Y et al. Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/-chimeric mice. Blood 2006; 107: 2243-2251.
12. Broxmeyer HE, Kohli L, Kim CH, Lee Y, Mantel C, Cooper S et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol 2003; 73: 630-638.
13. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000; 95: 756-768.
14. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998.
15. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730.
16. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cellmobilizing agent. Future Oncol 2007; 3: 19-27.
17. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007; 25: 2158-2166.
18. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996; 87: 4754-4761.
19. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5: 311-321.
20. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
21. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
22. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998; 91: 2406-2414.
23. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150-1157.
24. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-596.
25. Kato I, Niwa A, Heike T, Fujino H, Saito MK, Umeda K et al. Identification of Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-1/CXCR4 Axis. PLoS One 2011; 6: e27042.
26. Tavor S, Petit I, Porozov S, Goichberg P, Avigdor A, Sagiv S et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood 2005; 106: 2120-2127.
27. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786-791.
28. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-557.
29. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
30. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
31. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924.
32. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673.
33. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 2003; 12: 185-195.
34. Lataillade JJ, Clay D, Bourin P, Herodin F, Dupuy C, Jasmin C et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood 2002; 99: 1117-1129.
35. Lee Y, Gotoh A, Kwon HJ, You M, Kohli L, Mantel C et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 2002; 99: 4307-4317.
36. Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2008; 17: 319-326.
37. Zhang Y, Foudi A, Geay JF, Berthebaud M, Buet D, Jarrier P et al. Intracellular localization and constitutive endocytosis of CXCR4 in human CD34+ hematopoietic progenitor cells. Stem Cells 2004; 22: 1015-1029.
38. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
39. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem 2004; 279: 43854-43860.
40. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817-2824.
41. Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 115: 545-553.
42. Eppert KA, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen PA et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093.
43. Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 2011; 25: 1286-1296.
44. Zhang Y, Wittner M, Bouamar H, Jarrier P, Vainchenker W, Louache F. Identification of CXCR4 as a new nitric oxide-regulated gene in human CD34+ cells. Stem Cells 2007; 25: 211-219.
45. Marandin A, Katz A, Oksenhendler E, Tulliez M, Picard F, Vainchenker W et al. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood 1996; 88: 4568-4578.